RxDoctor Payments Data

Lucia Diaz

Pediatric Dermatology · Austin, TXNPI 1043454515

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $3,120 of the $3,957 with a category attached, or 78.8%. Regeneron accounts for 78.8% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2020 at $3,326 and has fallen 96.2% since, to $126 in 2025.

$3,957in general payments, 2019–2025

Across 33 payments — averaging $119.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron$3K
  • AbbVie$184
  • Sanofi$113
  • Incyte Corporation$108
  • Regeneron Healthcare Solutions, Inc.$100
  • Sanofi-aventis U.S. LLC$100
  • plus $232 from 7 others
$617,034in research payments, 2019–2025

Across 236 payments — averaging $2614.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$495K
  • Janssen Research & Development, LLC$90K
  • Sanofi US Services Inc.$21K
  • Pfizer$11K
  • Incyte Corporation$45

What the payments were for

  • Consulting fees$3,12079%
  • Food & beverage$49613%
  • Education$3419%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few pediatric dermatology providers in Texasto place this figure against a meaningful peer group, so we don't.

Other pediatric dermatology in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →